Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests tailored Weight-Loss program for obesity

NCT ID NCT07465341

Disease control Sponsor: University of Michigan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a program called MiWeigh that helps people with obesity and related conditions like diabetes or high blood pressure lose weight. Participants get a personalized plan from a doctor, access to a website, and weekly check-ins. The goal is to see if this approach leads to more weight loss than just giving people information.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
behavioral intervention: personalized weight-loss program with doctor visits and weekly check-ins
What this could lead to
If successful, this program could offer a practical, scalable way for healthcare systems to help people with obesity lose weight and manage related health issues.
What could go wrong
This is a behavioral study, not a drug trial, so results depend on participant motivation. It is still recruiting and outcomes are measured at 12 months, so long-term effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Body Mass index (BMI) 30 kilogram per square meter or higher * Diagnosed with one or more of the following weight-related conditions: * Type 2 Diabetes * Prediabetes Mellitus * Hyperlipidemia (HLP) * Hypertension (HTN) * Polycystic Ovary Syndrome (PCOS) * Obstructive Sleep Apnea (OSA) and/or * Metabolic dysfunction-associated steatotic liver disease (MASLD) * Speaks English * Interest in losing weight * Willingness to complete assessments per study protocol * Willing and able to use the Electronic health records patient portal to respond to messages * Willing to report weight weekly by text if randomized to intervention arm * Able to see provider virtually at certain days/times up to four times in a year Exclusion Criteria: * ≥ 5% weight loss within the prior 12 months * Has had a Weight Navigation Program visit in past * Pregnant, planning a pregnancy, or breastfeeding in the next year * Ongoing participation in another weight-loss program * Taking an anti-obesity medication * Ever diagnosed with Type 1 Diabetes Mellitus (per protocol) * Dementia * Serious uncontrolled mental health conditions as indicated (per protocol) * Chronic kidney disease, Stage 4 or higher * Alcohol dependence and opioid dependence (per protocol) * History of anorexia or bulimia * Bariatric/ gastric bypass surgery, gastric sleeve surgery, or gastric balloon procedure in last year * Currently enrolled in an interventional research study that is examining how a diet, program, or drug might: promote physical exercise, healthy eating habits, or weight loss; lower blood pressure; or lower blood sugar * Not planning to live in local area over the next year * Intensive cancer treatment such as bone marrow transplant, chemotherapy, radiation, or cancer related surgery (not including hormonal chemotherapy like Tamoxifen) in last six months or next 12 months * Other serious health issues or personal concerns that could prevent participant from completing study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperlipidemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperlipidemia hypertensive disorder metabolic dysfunction-associated steatotic liver disease Obesity obesity disorder obstructive sleep apnea syndrome polycystic ovary syndrome prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.